<DOC>
	<DOC>NCT00789737</DOC>
	<brief_summary>The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone. The study will evaluate if Welchol monotherapy for Type 2 Diabetes Mellitus will be safe, well tolerated and efficacious.</brief_summary>
	<brief_title>Welchol as Monotherapy for Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Male or female subjects &gt;= 18 years of age; Women of childbearing potential (WOCBP) must be using an adequate method of contraception as detailed in the protocol. Diagnosis of Type 2 Diabetes Mellitus; HbA1C &gt;= 7.5% and =&lt; 9.5 % at screening; Fasting Cpeptide &gt;0.5 ng/mL at screening; Drug na√Øve (no prior treatment with OAD) or having received no pharmacologic therapy for diabetes for the 3 month period prior to screening; Clinically stable in regards to medical conditions other than type 2 diabetes; Concomitant medications must be at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period; and Fasting glucose =&lt; 240 mg/dL at randomization A history of type 1 diabetes and/or a history of ketoacidosis; History of bowel obstruction; History of hypertriglyceridemiainduced pancreatitis; Fasting serum triglyceride concentrations &gt;500 mg/dL; History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal (GI) motility disorders, or major GI surgery; History of insulin use of &gt;= 2 weeks duration in the previous 3 months or a total of &gt; 2 months of insulin therapy at any time prior to screening; Two or more fasting selfmonitored blood glucose (SMBG) levels &gt;240 mg/dL during the placebo leadin period. Previous treatment with a bile acid sequestrant, including Welchol within the 3 months prior to screening; Body mass index (BMI) &gt;40 kg/m2; Weight loss &gt; 3% in prior 3 months; and LDL &lt;60 mg/dL.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>